A Phase 3 interventional study of pregabalin and pregabalin in Osteoarthritis and Postoperative Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 170th largest by enrollment of the 832 interventional ones that give a count, is one of 42 that started in 2007, is one of 128 in phase 3, and was the 119th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Columbia University · Sites in United States
Ages 18+
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 42 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 759 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 5 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
60 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin
Drug: pregabalin
Drug: Placebo
150 milligram (mg)/ day (double blind)
300 mg/day (double blind)
Placebo
Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)
The mBPI-SF is a self administered questionnaire developed to assess pain severity and pain interference with functional activities during a 24-hour period prior to evaluation. For the Worst Pain item of the m-BPI-sf scale (11 point Likert scale; range: 0 \[no pain\] to 10 \[pain as bad as you can imagine\]), subjects were asked to rate their pain by marking an "X" in one of the ten boxes that best described their pain at its worst in the last 24 hours post surgery and at least 12 hours after discontinuation of the peripheral nerve block or neuroaxial block.
Time frame: 48 hours after surgery
Cumulative Total Amount of Opioids Used During the Entire Hospital Stay
Total cumulative dose calculated as mg of oral morphine equivalent and included opioids given by any route (patient controlled analgesia \[PCA\] pump, parenteral bolus or oral). Results for daily total not including pregabalin (not an opioid). Statistical model included main effect of treatment group and center. 1 subject at 144 h, 300 mg=non-missing data. Due to small sample size (N=1, 300 mg; N=5, other groups) and large opioid consumption for another subject in same center, least squares mean (300 mg, 144 h) is negative.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours
Opioids Used Post Discharge
The amount of opioid use was calculated as mg of oral morphine equivalent and included opioids administered by any route (PCA pump, parenteral bolus, or oral). Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period. This outcome measure does not include pregabalin as it is not an opioid.
Time frame: Week 2, Week 4, Week 6/Early Termination (ET)
Analgesics Used During the Hospital Stay (Acetylsalicylic Acid, Ketorolac, and Paracetamol)
Total dose for in-hospital visits was the total dose for the day.
Time frame: 24 hours, 48 hours, 72 hours
Analgesics Used Post Discharge (Acetylsalicylic Acid [Week 2] and Paracetamol [Weeks 2, 4, and 6]
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 2, Week 4, Week 6/ET
Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 2, Week 4, Week 6/ET
Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 300 mg Treatment Group
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 2, Week 4, Week 6/ET
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4
Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 4
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg Treatment Group at Week 4
Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 4
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET
Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 6/ET
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg and Placebo Treatment Groups at Week 6/ET
Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
Time frame: Week 6/ET
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the Opioid-Related Symptom Distress Scale (OR-SDS) - Frequency Composite Score
The OR-SDS was used to assess subject-reported levels of frequency concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom frequency was rated as: 1=rarely, 2=occasionally, 3=frequently, or 4=almost constantly. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible frequency score: 0 (less frequent) to 4 (more frequent).
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score
The OR-SDS was used to assess subject-reported levels of severity concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom severity was rated as: 1=slight, 2=moderate, 3=severe, or 4=very severe. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible severity score: 0 (less severe) to 4 (more severe).
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Degree of Bother Composite Score
The OR-SDS was used to assess subject-reported level of degree of bother concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom degree of bother was rated as: 1=not at all, 2=a little bit, 3=somewhat, 4=quite a bit, or 5=very much. Average score for each symptom was calculated by taking the mean of patient-reported score. Total possible degree of bother score: 0 (less degree of bother) to 5 (greater degree of bother).
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score
The OR-SDS assessed subject-reported levels of frequency, severity and degree of bother for 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, retching and vomiting. The overall composite score was the average across frequency, severity, and degree of bother scores. Total possible score: 0 (better) to 4.34 (worse).
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
Total Clinically Meaningful Event (CME) Score
CMEs were defined using OR-SDS (assesses subject-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe or very severe, with the exception of confusion. Confusion was defined as a CME if the severity score was at least moderate. Total score = the sum of CMEs across symptoms. Each CME = 1 point. Total CME score ranges from 0 to 9.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, and Week 6/ET
Pain Interference Index Score as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Pain interference index = average of pain interference question (Q) 5A to 5G. Questions were asked as follows: how, during the past 24 hours, has pain interfered with general activity (Q5A), mood (Q5B), walking ability (Q5C), normal work (outside home and housework) (Q5D), relations with other people (Q5E), sleep (Q5F), enjoyment of life (Q5G). Scale: 0=does not interfere to 10=completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Relations With People as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With General Activity as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Mood as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Walking Ability as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Normal Work as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Pain Interference With Sleep as Measured by the m-BPI-sf
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes.
Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Daily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)
Subject rated scale for worst pain over the last 24 hours. Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.
Time frame: 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET
Daily and Weekly Average Pain During the Hospital Stay and Post Discharge Assessed by the Pain NRS
Subject rated scale for average pain intensity over the last 24 hours. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.
Time frame: 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET
Current Pain During the Hospital Stay Assessed by the Pain NRS
Subject rated scale for average pain intensity over the last 24 hours. Pain was assessed using the question "How much pain do you have right now?" Scores range from 0 (no pain) to 10 (most possible pain).
Time frame: 4, 8, 12, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, 184, and 192 hours during the hospital stay
Pain-Related Sleep Interference Post Surgery
The NRS-Sleep: subject rated 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]) rating how pain has interfered with sleep during the past 24 hours. Weekly mean scores were calculated post hospital discharge.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours 120 hours, 144 hours, 168 hours, and 192 hours post-surgery, Week 2, Week 4, Week 6/ET
Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery
VAS-Anxiety was administered to measure pre-operative anxiety. Score: 0 = no anxiety to 100 = worst imaginable anxiety.
Time frame: Day 1, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours prior to surgery
Timed Up-and-Go (TUG)
TUG: time taken in seconds to rise from a standard arm chair, walk to a line on the floor 3 meters away, turn, return and sit down again.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Week 2, Week 4, Week 6/ET
Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee
The degree of active (patient moving the knee) knee flexion and extension tolerated by each subject was recorded. Active ROM in the sitting position was assessed with a goniometer.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET
ROM Assessment of the Passive Flexion of the Surgical Knee
The degree of passive (movement of the knee with the aid of physical therapist or designee) knee flexion and extension tolerated by each subject was recorded. Passive ROM in the sitting position was assessed with a goniometer.
Time frame: 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET
Time From End of Surgery to Meet Hospital Discharge Criteria
The analysis was performed by Kaplan-Meier method with log-rank test.
Time frame: time from end of surgery up to 192 hours post surgery
Time From End of Surgery to Actual Discharge
The analysis was performed by Kaplan-Meier method with log-rank test.
Time frame: time from end of surgery up to 192 hours post surgery
Satisfaction With Current Pain Medication Measured by the Pain Treatment Satisfaction Scale (PTSS)
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
Time frame: Discharge, Week 2, Week 4, Week 6/ET
Satisfaction With Medication Characteristics Measured by the PTSS
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
Time frame: Discharge, Week 2, Week 4, Week 6/ET
Satisfaction With Medication Efficacy Measured by the PTSS
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
Time frame: Discharge, Week 2, Week 4, Week 6/ET
Overall Satisfaction Measured by the PTSS
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
Time frame: Discharge, Week 2, Week 4, and Week 6/ET
Overall Pain Relief Measured by the PTSS
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
Time frame: Discharge, Week 2, Week 4, and Week 6/ET
Number of Subjects With Global Evaluation of Study Medication Scores
The Global Evaluation of Study Medication is a subject-administered single item instrument that records the subject's overall impression (global evaluation) of the study medication by asking the following question: how would you rate the study medication you received for pain? The subject chooses based on a scale of 1 (poor), 2 (fair), 3 (good), or 4 (excellent).
Time frame: Discharge, Week 2, Week 4, and Week 6/ET
Number of Subjects With Persistent Pain Based on 11-Point Verbal Rating Scale (VRS)
The presence of persistent pain was evaluated on the 11-point VRS. The subject answered the question: how much pain did you experience in the last 24 hours in your operated knee? A zero score of VRS was the only number considered as a "no." Any positive score (1-10) of VRS was consider as "yes."
Time frame: Month 3, Month 6 (phone call)
Neuropathic Pain Symptom Inventory (NPSI)
NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.
Time frame: Month 3, Month 6 (phone call)
| Milestone | Pregabalin (150 Milligrams [mg]) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Started | 103 | 100 | 104 |
| Received treatment | 98 | 96 | 98 |
| Completed | 77 | 63 | 71 |
| Not completed | 26 | 37 | 33 |
| Withdrew: Adverse event | 11 | 17 | 13 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Other | 4 | 9 | 6 |
| Withdrew: Withdrawal by subject | 5 | 5 | 7 |
| Withdrew: Randomized but not treated | 5 | 4 | 6 |
The mBPI-SF is a self administered questionnaire developed to assess pain severity and pain interference with functional activities during a 24-hour period prior to evaluation. For the Worst Pain item of the m-BPI-sf scale (11 point Likert scale; range: 0 \[no pain\] to 10 \[pain as bad as you can imagine\]), subjects were asked to rate their pain by marking an "X" in one of the ten boxes that best described their pain at its worst in the last 24 hours post surgery and at least 12 hours after discontinuation of the peripheral nerve block or neuroaxial block.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf) | 7.041 ± 0.267 | 6.740 ± 0.264 | 7.079 ± 0.279 |
Total cumulative dose calculated as mg of oral morphine equivalent and included opioids given by any route (patient controlled analgesia \[PCA\] pump, parenteral bolus or oral). Results for daily total not including pregabalin (not an opioid). Statistical model included main effect of treatment group and center. 1 subject at 144 h, 300 mg=non-missing data. Due to small sample size (N=1, 300 mg; N=5, other groups) and large opioid consumption for another subject in same center, least squares mean (300 mg, 144 h) is negative.
| mg of oral morphine equivalent | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=85, 86, 84) | 151.790 ± 14.210 | 152.306 ± 14.313 | 167.854 ± 14.573 |
| 48 hours (n=82, 81, 83) | 86.402 ± 12.057 | 93.846 ± 12.292 | 122.830 ± 12.304 |
| 72 hours (n=60, 60, 60) | 55.654 ± 9.175 | 48.713 ± 9.420 | 52.895 ± 9.851 |
| 96 hours (n=32, 39, 35) | 31.976 ± 7.928 | 24.758 ± 7.861 | 35.332 ± 8.354 |
| 120 hours (n=12, 6, 13) | 27.520 ± 13.146 | 14.235 ± 17.684 | 27.559 ± 13.306 |
| 144 hours (n=5, 1, 5) | 33.956 ± 12.019 | -64.544 ± 28.633 | 73.956 ± 16.720 |
The amount of opioid use was calculated as mg of oral morphine equivalent and included opioids administered by any route (PCA pump, parenteral bolus, or oral). Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period. This outcome measure does not include pregabalin as it is not an opioid.
| mg of oral morphine equivalent | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Week 2 (n=41, 40, 36) | 30.255 ± 3.515 | 27.692 ± 3.534 | 26.119 ± 3.789 |
| Week 4 (n=33, 33, 30) | 37.130 ± 4.975 | 37.507 ± 4.911 | 34.271 ± 5.274 |
| Week 6/ET (n=24, 28, 22) | 38.686 ± 6.261 | 35.945 ± 5.888 | 35.036 ± 6.401 |
Total dose for in-hospital visits was the total dose for the day.
| mg | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Acetylsalicylic Acid, 72 hours (n=3, 1, 1) | 235.175 ± 61.531 | 1442.025 ± 117.823 | 1425.825 ± 117.823 |
| Ketorolac, 24 hours, (n=1, 4, 3) | 32.961 ± 57.230 | 53.432 ± 28.615 | 27.189 ± 31.346 |
| Ketorolac, 48 hours, (n=2, 8, 4) | 20.553 ± 7.971 | 21.863 ± 3.862 | 23.473 ± 5.520 |
| Paracetamol, 24 hours (n=14, 20, 16) | 1311.246 ± 359.886 | 1363.086 ± 283.808 | 1380.481 ± 309.224 |
| Paracetamol, 48 hours (n=22, 25, 17) | 1357.030 ± 371.095 | 1368.880 ± 339.509 | 1263.337 ± 443.695 |
| Paracetamol, 72 hours (n=12, 13, 16) | 446.050 ± 445.588 | 877.916 ± 403.657 | 1128.355 ± 347.457 |
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
| mg | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Acetylsalicylic Acid, Week 2 (n=6, 1, 2) | 498.613 ± 130.446 | 797.463 ± 361.189 | 992.613 ± 291.687 |
| Paracetamol, Week 2 (n=7, 13, 7) | 603.496 ± 232.179 | 665.574 ± 164.777 | 630.787 ± 247.693 |
| Paracetamol, Week 4 (n=5, 12, 6) | 792.434 ± 412.260 | 779.226 ± 260.034 | 593.498 ± 375.124 |
| Paracetamol, Week 6/ET (n=6, 14, 5) | 1128.952 ± 290.993 | 1098.840 ± 223.948 | 1385.873 ± 334.859 |
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
| mg | Pregabalin (150 mg) | Placebo |
|---|---|---|
| Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups | 862.350 ± 584.827 | 983.850 ± 1119.858 |
Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
No measurements were reported for this outcome.
Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
| mg | Pregabalin (150 mg) | Placebo |
|---|---|---|
| Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4 | 650.000 ± 0.000 | 22.100 (22.100 to 22.100) |
Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
No measurements were reported for this outcome.
Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
| mg | Pregabalin (150 mg) |
|---|---|
| Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET | 513.163 ± 200.647 |
Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.
No measurements were reported for this outcome.
The OR-SDS was used to assess subject-reported levels of frequency concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom frequency was rated as: 1=rarely, 2=occasionally, 3=frequently, or 4=almost constantly. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible frequency score: 0 (less frequent) to 4 (more frequent).
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=72, 69, 69) | 0.767 ± 0.069 | 0.808 ± 0.072 | 0.888 ± 0.074 |
| 48 hours (n=83, 86, 76) | 0.782 ± 0.061 | 0.779 ± 0.060 | 0.908 ± 0.063 |
| 72 hours (n=81, 77, 73) | 0.669 ± 0.064 | 0.688 ± 0.066 | 0.726 ± 0.069 |
| 96 hours (n=49, 53, 54) | 0.623 ± 0.087 | 0.656 ± 0.083 | 0.676 ± 0.082 |
| 120 hours (n=19, 17, 23) | 0.427 ± 0.086 | 0.405 ± 0.087 | 0.446 ± 0.087 |
| Discharge (n=86, 85, 81) | 0.567 ± 0.056 | 0.619 ± 0.056 | 0.664 ± 0.058 |
| Week 2 (n=87, 78, 79) | 0.535 ± 0.056 | 0.525 ± 0.058 | 0.513 ± 0.059 |
| Week 4 (n=77, 69, 67) | 0.402 ± 0.048 | 0.415 ± 0.050 | 0.391 ± 0.053 |
| Week 6/ET (n=78, 66, 71) | 0.249 ± 0.043 | 0.386 ± 0.047 | 0.239 ± 0.047 |
The OR-SDS was used to assess subject-reported levels of severity concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom severity was rated as: 1=slight, 2=moderate, 3=severe, or 4=very severe. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible severity score: 0 (less severe) to 4 (more severe).
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=72, 69, 69) | 0.579 ± 0.059 | 0.590 ± 0.061 | 0.621 ± 0.062 |
| 48 hours (n=83, 86, 77) | 0.642 ± 0.051 | 0.624 ± 0.050 | 0.695 ± 0.053 |
| 72 hours (n=81, 77, 73) | 0.539 ± 0.054 | 0.534 ± 0.055 | 0.562 ± 0.057 |
| 96 hours (n=49, 53, 54) | 0.509 ± 0.070 | 0.502 ± 0.067 | 0.535 ± 0.066 |
| 120 hours (n=19, 17, 23) | 0.366 ± 0.066 | 0.334 ± 0.067 | 0.391 ± 0.066 |
| Discharge (n=86, 85, 82) | 0.451 ± 0.048 | 0.495 ± 0.048 | 0.488 ± 0.049 |
| Week 2 (n=87, 78, 79) | 0.390 ± 0.043 | 0.375 ± 0.045 | 0.364 ± 0.045 |
| Week 4 (n=77, 69, 67) | 0.269 ± 0.034 | 0.308 ± 0.036 | 0.247 ± 0.037 |
| Week 6/ET (n=78, 66, 71) | 0.182 ± 0.034 | 0.282 ± 0.037 | 0.175 ± 0.037 |
The OR-SDS was used to assess subject-reported level of degree of bother concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom degree of bother was rated as: 1=not at all, 2=a little bit, 3=somewhat, 4=quite a bit, or 5=very much. Average score for each symptom was calculated by taking the mean of patient-reported score. Total possible degree of bother score: 0 (less degree of bother) to 5 (greater degree of bother).
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=72, 69, 69) | 0.671 ± 0.081 | 0.788 ± 0.084 | 0.836 ± 0.086 |
| 48 hours (n=83, 86, 77) | 0.810 ± 0.067 | 0.769 ± 0.066 | 0.918 ± 0.070 |
| 72 hours (n=81, 77, 73) | 0.686 ± 0.077 | 0.694 ± 0.080 | 0.822 ± 0.083 |
| 96 hours (n=49, 53, 54) | 0.572 ± 0.096 | 0.623 ± 0.092 | 0.703 ± 0.090 |
| 120 hours (n=19, 17, 23) | 0.565 ± 0.111 | 0.439 ± 0.113 | 0.574 ± 0.113 |
| Discharge (n=86, 85, 82) | 0.575 ± 0.067 | 0.616 ± 0.067 | 0.697 ± 0.069 |
| Week 2 (n=87, 78, 79) | 0.527 ± 0.063 | 0.506 ± 0.066 | 0.533 ± 0.067 |
| Week 4 (n=77, 69, 67) | 0.395 ± 0.053 | 0.433 ± 0.055 | 0.354 ± 0.058 |
| Week 6/ET (n=78, 66, 71) | 0.260 ± 0.049 | 0.401 ± 0.053 | 0.274 ± 0.053 |
The OR-SDS assessed subject-reported levels of frequency, severity and degree of bother for 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, retching and vomiting. The overall composite score was the average across frequency, severity, and degree of bother scores. Total possible score: 0 (better) to 4.34 (worse).
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=72, 69, 69) | 0.669 ± 0.067 | 0.727 ± 0.069 | 0.778 ± 0.071 |
| 48 hours (n=83, 86, 77) | 0.743 ± 0.056 | 0.722 ± 0.055 | 0.838 ± 0.059 |
| 72 hours (n=81, 77, 73) | 0.630 ± 0.063 | 0.637 ± 0.065 | 0.703 ± 0.067 |
| 96 hours (n=49, 53, 54) | 0.567 ± 0.082 | 0.593 ± 0.079 | 0.637 ± 0.077 |
| 120 hours (n=19, 17, 23) | 0.453 ± 0.084 | 0.393 ± 0.086 | 0.471 ± 0.085 |
| Discharge (n=86, 85, 82) | 0.530 ± 0.055 | 0.575 ± 0.055 | 0.615 ± 0.056 |
| Week 2 (n=87, 78, 79) | 0.482 ± 0.052 | 0.467 ± 0.055 | 0.469 ± 0.056 |
| Week 4 (n=77, 69, 67) | 0.354 ± 0.044 | 0.384 ± 0.046 | 0.329 ± 0.048 |
| Week 6/ET (n=78, 66, 71) | 0.230 ± 0.041 | 0.355 ± 0.045 | 0.229 ± 0.045 |
CMEs were defined using OR-SDS (assesses subject-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe or very severe, with the exception of confusion. Confusion was defined as a CME if the severity score was at least moderate. Total score = the sum of CMEs across symptoms. Each CME = 1 point. Total CME score ranges from 0 to 9.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=72, 69, 69) | 0.822 ± 0.161 | 0.817 ± 0.166 | 0.772 ± 0.171 |
| 48 hours (n=83, 86, 87) | 0.814 ± 0.141 | 0.834 ± 0.138 | 0.789 ± 0.146 |
| 72 hours (n=81, 77, 73) | 0.647 ± 0.134 | 0.570 ± 0.138 | 0.613 ± 0.144 |
| 96 hours (n=49, 53, 54) | 0.440 ± 0.173 | 0.489 ± 0.164 | 0.284 ± 0.162 |
| 120 hours (n=19, 17, 23) | 0.178 ± 0.089 | 0.350 ± 0.091 | 0.246 ± 0.090 |
| Discharge (n=86, 85, 82) | 0.429 ± 0.113 | 0.502 ± 0.114 | 0.352 ± 0.117 |
| Week 2 (n=87, 78, 79) | 0.328 ± 0.093 | 0.311 ± 0.097 | 0.171 ± 0.099 |
| Week 4 (n=77, 69, 67) | 0.116 ± 0.059 | 0.236 ± 0.062 | 0.032 ± 0.064 |
| Week 6/ET (n=78, 66, 71) | 0.059 ± 0.062 | 0.260 ± 0.068 | 0.051 ± 0.067 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Pain interference index = average of pain interference question (Q) 5A to 5G. Questions were asked as follows: how, during the past 24 hours, has pain interfered with general activity (Q5A), mood (Q5B), walking ability (Q5C), normal work (outside home and housework) (Q5D), relations with other people (Q5E), sleep (Q5F), enjoyment of life (Q5G). Scale: 0=does not interfere to 10=completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 3.427 ± 0.230 | 3.488 ± 0.230 | 3.887 ± 0.246 |
| Week 2 (n=86, 78, 80) | 2.969 ± 0.236 | 2.814 ± 0.245 | 3.037 ± 0.251 |
| Week 4 (n=77, 69, 67) | 2.162 ± 0.202 | 1.996 ± 0.208 | 2.094 ± 0.224 |
| Week 6/ET (n=78, 67, 71) | 1.597 ± 0.199 | 1.637 ± 0.214 | 1.662 ± 0.215 |
| Month 3 (n=30, 32, 35) | 1.139 ± 0.367 | 1.335 ± 0.375 | 1.629 ± 0.366 |
| Month 6 (n=31, 25, 27) | 1.513 ± 0.264 | 1.300 ± 0.241 | 0.852 ± 0.253 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 1.837 ± 0.266 | 1.716 ± 0.266 | 2.624 ± 0.284 |
| Week 2 (n=86, 78, 80) | 1.566 ± 0.231 | 1.370 ± 0.240 | 1.671 ± 0.246 |
| Week 4 (n=77, 69, 67) | 1.004 ± 0.215 | 1.162 ± 0.222 | 1.187 ± 0.238 |
| Week 6/ET (n=78, 67, 71) | 0.544 ± 0.171 | 0.845 ± 0.184 | 0.898 ± 0.185 |
| Month 3 (n=30, 32, 35) | 0.253 ± 0.377 | 0.861 ± 0.377 | 1.364 ± 0.365 |
| Month 6 (n=31, 25, 27) | 0.802 ± 0.245 | 1.060 ± 0.226 | 0.626 ± 0.235 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 3.487 ± 0.330 | 3.769 ± 0.330 | 3.744 ± 0.354 |
| Week 2 (n=86, 78, 80) | 2.945 ± 0.313 | 2.802 ± 0.325 | 2.953 ± 0.334 |
| Week 4 (n=77, 69, 67) | 2.152 ± 0.260 | 2.042 ± 0.268 | 1.768 ± 0.289 |
| Week 6/ET (n=78, 67, 71) | 1.535 ± 0.247 | 1.720 ± 0.266 | 1.696 ± 0.267 |
| Month 3 (n=30, 32, 35) | 0.944 ± 0.497 | 1.467 ± 0.513 | 1.368 ± 0.509 |
| Month 6 (n=31, 25, 27) | 1.657 ± 0.404 | 1.658 ± 0.367 | 0.663 ± 0.389 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 3.794 ± 0.317 | 4.499 ± 0.315 | 4.764 ± 0.336 |
| Week 2 (n=86, 78, 80) | 3.254 ± 0.278 | 3.526 ± 0.288 | 3.524 ± 0.294 |
| Week 4 (n=77, 69, 67) | 2.470 ± 0.237 | 2.417 ± 0.244 | 2.427 ± 0.260 |
| Week 6/ET (n=78, 67, 71) | 2.109 ± 0.245 | 1.902 ± 0.263 | 2.028 ± 0.263 |
| Month 3 (n=30, 32, 35) | 1.861 ± 0.505 | 1.547 ± 0.507 | 1.969 ± 0.492 |
| Month 6 (n=31, 25, 27) | 1.738 ± 0.412 | 1.717 ± 0.376 | 1.410 ± 0.394 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 2.588 ± 0.292 | 2.418 ± 0.291 | 3.354 ± 0.310 |
| Week 2 (n=86, 78, 80) | 2.640 ± 0.292 | 2.115 ± 0.303 | 2.554 ± 0.308 |
| Week 4 (n=77, 69, 67) | 1.590 ± 0.253 | 1.511 ± 0.261 | 1.530 ± 0.279 |
| Week 6/ET (n=78, 67, 71) | 1.053 ± 0.230 | 1.171 ± 0.247 | 1.325 ± 0.247 |
| Month 3 (n=30, 32, 35) | 0.632 ± 0.328 | 0.956 ± 0.339 | 1.334 ± 0.322 |
| Month 6 (n=31, 25, 27) | 1.201 ± 0.326 | 0.832 ± 0.297 | 0.369 ± 0.313 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 4.918 ± 0.320 | 4.728 ± 0.319 | 4.982 ± 0.342 |
| Week 2 (n=86, 78, 80) | 3.297 ± 0.278 | 3.344 ± 0.289 | 3.425 ± 0.296 |
| Week 4 (n=77, 69, 67) | 2.646 ± 0.259 | 2.108 ± 0.267 | 2.442 ± 0.286 |
| Week 6/ET (n=78, 67, 71) | 2.004 ± 0.237 | 1.886 ± 0.254 | 1.742 ± 0.256 |
| Month 3 (n=30, 32, 35) | 1.439 ± 0.419 | 1.907 ± 0.434 | 1.928 ± 0.414 |
| Month 6 (n=31, 25, 27) | 1.573 ± 0.322 | 1.391 ± 0.293 | 1.126 ± 0.308 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=82, 77, 72) | 4.879 ± 0.390 | 4.738 ± 0.395 | 4.873 ± 0.418 |
| Week 2 (n=86, 78, 79) | 4.010 ± 0.335 | 3.539 ± 0.347 | 3.831 ± 0.355 |
| Week 4 (n=77, 69, 67) | 2.833 ± 0.275 | 2.500 ± 0.285 | 2.895 ± 0.305 |
| Week 6/ET (n=78, 67, 71) | 2.133 ± 0.269 | 2.152 ± 0.291 | 2.040 ± 0.291 |
| Month 3 (n=30, 32, 35) | 1.797 ± 0.510 | 1.731 ± 0.520 | 2.264 ± 0.507 |
| Month 6 (n=31, 25, 27) | 1.627 ± 0.288 | 1.349 ± 0.263 | 1.029 ± 0.276 |
m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=83, 80, 74) | 2.696 ± 0.299 | 2.642 ± 0.299 | 3.307 ± 0.318 |
| Week 2 (n=86, 78, 80) | 3.139 ± 0.333 | 3.015 ± 0.345 | 3.587 ± 0.353 |
| Week 4 (n=77, 69, 67) | 2.478 ± 0.278 | 2.166 ± 0.288 | 2.668 ± 0.308 |
| Week 6/ET (n=78, 67, 71) | 1.847 ± 0.275 | 1.701 ± 0.296 | 2.070 ± 0.296 |
| Month 3 (n=30, 32, 35) | 1.276 ± 0.537 | 0.941 ± 0.548 | 1.499 ± 0.526 |
| Month 6 (n=31, 25, 27) | 1.963 ± 0.482 | 1.005 ± 0.439 | 0.778 ± 0.464 |
Subject rated scale for worst pain over the last 24 hours. Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 12 hours (n=29, 28, 28) | 7.217 ± 0.597 | 7.002 ± 0.649 | 8.770 ± 0.635 |
| 24 hours (n=82, 79, 74) | 7.477 ± 0.298 | 7.290 ± 0.301 | 7.201 ± 0.311 |
| 48 hours (n=78, 82, 75) | 7.041 ± 0.267 | 6.740 ± 0.264 | 7.079 ± 0.279 |
| 72 hours (n=56, 52, 55) | 6.322 ± 0.333 | 5.977 ± 0.350 | 5.964 ± 0.343 |
| 96 hours (n=20, 21, 26) | 6.703 ± 0.624 | 4.711 ± 0.618 | 6.556 ± 0.598 |
| 120 hours (n=5, 3, 9) | 5.915 ± 0.819 | 4.346 ± 1.446 | 7.056 ± 0.663 |
| Week 2 (n=79, 72, 72) | 5.255 ± 0.209 | 5.592 ± 0.223 | 5.396 ± 0.229 |
| Week 4 (n=76, 65, 67) | 4.134 ± 0.220 | 4.043 ± 0.241 | 4.280 ± 0.247 |
| Week 6/ET (n=61, 55, 59) | 3.455 ± 0.267 | 3.425 ± 0.276 | 3.350 ± 0.292 |
Subject rated scale for average pain intensity over the last 24 hours. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 12 hours (n=29, 28, 28) | 5.712 ± 0.550 | 4.845 ± 0.593 | 6.748 ± 0.600 |
| 24 hours (n=81, 79, 74) | 4.961 ± 0.255 | 4.614 ± 0.257 | 4.918 ± 0.266 |
| 48 hours (n=78, 82, 75) | 4.518 ± 0.238 | 4.309 ± 0.236 | 4.515 ± 0.249 |
| 72 hours (n=56, 51, 55) | 4.281 ± 0.280 | 3.740 ± 0.298 | 4.186 ± 0.290 |
| 96 hours (n=20, 21, 26) | 4.842 ± 0.514 | 3.126 ± 0.503 | 4.741 ± 0.488 |
| 120 hours (n=5, 3, 9) | 4.211 ± 1.002 | 2.940 ± 1.566 | 4.287 ± 0.759 |
| Week 2 (n=79, 72, 71) | 3.691 ± 0.186 | 3.974 ± 0.198 | 3.987 ± 0.206 |
| Week 4 (n=76, 65, 67) | 2.956 ± 0.180 | 2.845 ± 0.197 | 3.163 ± 0.203 |
| Week 6/ET (n=60, 54, 59) | 2.374 ± 0.215 | 2.385 ± 0.225 | 2.389 ± 0.234 |
Subject rated scale for average pain intensity over the last 24 hours. Pain was assessed using the question "How much pain do you have right now?" Scores range from 0 (no pain) to 10 (most possible pain).
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 4 hours (n=84, 84, 78) | 4.940 ± 0.345 | 3.554 ± 0.344 | 4.363 ± 0.361 |
| 8 hours (n=82, 79, 75) | 5.083 ± 0.305 | 4.529 ± 0.312 | 5.119 ± 0.323 |
| 12 hours (n=66, 68, 64) | 4.779 ± 0.385 | 4.068 ± 0.375 | 4.784 ± 0.376 |
| 24 hours (n=87, 88, 82) | 4.500 ± 0.265 | 4.545 ± 0.262 | 4.836 ± 0.277 |
| 32 hours (n=79, 78, 69) | 4.450 ± 0.293 | 4.507 ± 0.296 | 4.345 ± 0.315 |
| 40 hours (n=62, 55, 55) | 3.720 ± 0.401 | 3.821 ± 0.412 | 3.902 ± 0.408 |
| 48 hours (n=78, 72, 70) | 4.095 ± 0.276 | 4.069 ± 0.284 | 3.785 ± 0.295 |
| 56 hours (n=62, 56, 57) | 4.015 ± 0.329 | 3.358 ± 0.345 | 3.760 ± 0.343 |
| 64 hours (n=46, 37, 45) | 4.220 ± 0.458 | 3.492 ± 0.480 | 4.578 ± 0.423 |
| 72 hours (n=51, 45, 45) | 3.971 ± 0.344 | 3.271 ± 0.379 | 3.826 ± 0.385 |
| 80 hours (n=19, 24, 24) | 5.312 ± 0.678 | 2.403 ± 0.624 | 4.285 ± 0.691 |
| 88 hours (n=16, 13, 20) | 4.265 ± 0.714 | 2.767 ± 0.803 | 3.914 ± 0.730 |
| 96 hours (n=16, 14, 20) | 3.525 ± 0.729 | 2.532 ± 0.773 | 2.658 ± 0.737 |
| 104 hours (n=7, 3, 7) | 3.501 ± 0.908 | 2.680 ± 1.382 | 1.829 ± 0.972 |
The NRS-Sleep: subject rated 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]) rating how pain has interfered with sleep during the past 24 hours. Weekly mean scores were calculated post hospital discharge.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=86, 86, 81) | 4.452 ± 0.359 | 3.671 ± 0.364 | 5.481 ± 0.376 |
| 48 hours (n=82, 82, 77) | 3.830 ± 0.293 | 3.408 ± 0.296 | 4.027 ± 0.309 |
| 72 hours (n=59, 58, 59) | 2.926 ± 0.332 | 2.609 ± 0.349 | 3.645 ± 0.345 |
| 96 hours (n=20, 21, 24) | 4.087 ± 0.539 | 1.645 ± 0.522 | 3.213 ± 0.563 |
| 120 hours (n=6, 4, 7) | 3.194 ± 1.665 | 7.237 ± 2.563 | 1.328 ± 1.598 |
| Week 2 (n=80, 73, 71) | 3.837 ± 0.217 | 4.128 ± 0.229 | 4.256 ± 0.239 |
| Week 4 (n=76, 65, 67) | 3.181 ± 0.216 | 3.042 ± 0.236 | 3.532 ± 0.241 |
| Week 6/ET (n=61, 56, 57) | 2.484 ± 0.261 | 2.592 ± 0.265 | 2.748 ± 0.284 |
VAS-Anxiety was administered to measure pre-operative anxiety. Score: 0 = no anxiety to 100 = worst imaginable anxiety.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Day 1 (n=83, 79, 78) | 6.133 ± 2.395 | 7.103 ± 2.450 | 6.992 ± 2.523 |
| 1 hour (n=68, 67, 59) | 6.974 ± 2.787 | 3.272 ± 2.805 | 6.085 ± 3.013 |
| 2 hours (n=75, 76, 63) | 3.792 ± 2.860 | 6.818 ± 2.844 | 6.454 ± 3.126 |
| 3 hours (n=52, 58, 63) | 7.477 ± 3.466 | 7.588 ± 3.188 | 7.313 ± 3.108 |
| 4 hours (n=19, 17, 20) | 8.218 ± 5.803 | 0.109 ± 6.150 | 10.133 ± 5.527 |
| 5 hours (n=3, 4, 8) | 71.190 ± 16.886 | 29.819 ± 7.644 | -15.145 ± 6.572 |
TUG: time taken in seconds to rise from a standard arm chair, walk to a line on the floor 3 meters away, turn, return and sit down again.
| seconds | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=45, 47, 46) | 76.153 ± 10.449 | 79.973 ± 8.719 | 82.964 ± 10.174 |
| 48 hours (n=69, 70, 64) | 80.027 ± 8.601 | 79.548 ± 8.111 | 86.842 ± 8.927 |
| 72 hours (n=46, 46, 46) | 66.228 ± 8.429 | 68.373 ± 8.561 | 80.142 ± 9.276 |
| 96 hours (n=14, 14, 22) | 110.780 ± 45.437 | 43.021 ± 36.751 | 70.271 ± 37.742 |
| 120 hours (n=5, 2, 5) | 52.591 ± 5.102 | NA ± NA | 34.078 ± 4.700 |
| Week 2 (n=78, 71, 72) | 22.322 ± 2.087 | 21.332 ± 2.091 | 21.678 ± 2.113 |
| Week 4 (n=73, 65, 63) | 18.072 ± 1.537 | 18.145 ± 1.527 | 16.535 ± 1.563 |
| Week 6/ET (n=75, 60, 63) | 12.694 ± 1.226 | 15.140 ± 1.437 | 13.813 ± 1.408 |
The degree of active (patient moving the knee) knee flexion and extension tolerated by each subject was recorded. Active ROM in the sitting position was assessed with a goniometer.
| degrees | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=74, 71, 68) | 54.877 ± 2.194 | 60.744 ± 2.248 | 55.738 ± 2.287 |
| 48 hours (n=76, 78, 67) | 69.981 ± 1.984 | 73.370 ± 1.967 | 69.178 ± 2.184 |
| 72 hours (n=52, 52, 50) | 76.516 ± 2.274 | 79.535 ± 2.348 | 75.588 ± 2.406 |
| 96 hours (n=17, 17, 24) | 78.624 ± 3.287 | 79.500 ± 2.936 | 74.194 ± 2.969 |
| 120 hours (n=6, 3, 6) | 80.694 ± 4.890 | 72.694 ± 7.881 | 81.765 ± 5.625 |
| Week 2 (n=73, 67, 69) | 89.917 ± 1.589 | 90.332 ± 1.656 | 87.992 ± 1.711 |
| Week 4 (n=65, 63, 62) | 98.883 ± 1.870 | 102.237 ± 1.914 | 96.921 ± 2.017 |
| Week 6/ET (n=67, 54, 63) | 105.352 ± 1.845 | 106.252 ± 2.137 | 103.980 ± 2.051 |
The degree of passive (movement of the knee with the aid of physical therapist or designee) knee flexion and extension tolerated by each subject was recorded. Passive ROM in the sitting position was assessed with a goniometer.
| degrees | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| 24 hours (n=81, 76, 73) | 66.720 ± 1.990 | 71.523 ± 2.098 | 64.991 ± 2.093 |
| 48 hours (n=78, 80, 70) | 77.714 ± 1.695 | 81.322 ± 1.675 | 76.813 ± 1.809 |
| 72 hours (n=53, 50, 53) | 84.154 ± 1.952 | 88.119 ± 2.041 | 80.984 ± 1.971 |
| 96 hours (n=17, 17, 24) | 86.471 ± 3.553 | 91.460 ± 3.174 | 80.287 ± 3.210 |
| 120 hours (n=5, 3, 6) | 92.160 ± 1.517 | 97.160 ± 2.381 | 79.218 ± 1.682 |
| Week 2 (n=79, 71, 73) | 94.767 ± 1.520 | 96.973 ± 1.606 | 93.642 ± 1.647 |
| Week 4 (n=72, 62, 65) | 104.548 ± 1.680 | 107.703 ± 1.835 | 101.932 ± 1.851 |
| Week 6/ET (n=74, 60, 66) | 110.318 ± 1.629 | 111.348 ± 1.884 | 108.944 ± 1.848 |
The analysis was performed by Kaplan-Meier method with log-rank test.
| hours | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Time From End of Surgery to Meet Hospital Discharge Criteria | 106.802 ± 6.059 | 112.966 ± 7.707 | 95.531 ± 3.385 |
The analysis was performed by Kaplan-Meier method with log-rank test.
| hours | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Time From End of Surgery to Actual Discharge | 75.709 ± 2.798 | 73.906 ± 2.404 | 78.451 ± 2.715 |
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=84, 84, 80) | 79.897 ± 1.802 | 80.706 ± 1.809 | 77.550 ± 1.890 |
| Week 2 (n=22, 20, 18) | 85.274 ± 4.689 | 85.294 ± 4.782 | 80.148 ± 5.201 |
| Week 4 (n=30, 27, 19) | 83.608 ± 3.012 | 84.728 ± 3.010 | 81.572 ± 3.765 |
| Week 6/ET (n=32, 31, 40) | 74.618 ± 3.922 | 76.925 ± 4.187 | 71.962 ± 4.044 |
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=84, 84, 80) | 85.733 ± 1.679 | 85.732 ± 1.685 | 81.556 ± 1.761 |
| Week 2 (n=22, 20, 18) | 91.880 ± 4.676 | 87.869 ± 4.769 | 84.583 ± 5.187 |
| Week 4 (n=30, 27, 19) | 88.492 ± 2.693 | 90.571 ± 2.691 | 84.323 ± 3.366 |
| Week 6/ET (n=32, 31, 40) | 82.339 ± 3.729 | 84.571 ± 3.980 | 76.908 ± 3.845 |
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=84, 84, 80) | 74.156 ± 2.276 | 75.705 ± 2.284 | 73.577 ± 2.387 |
| Week 2 (n=22, 20, 18) | 78.669 ± 6.010 | 82.724 ± 6.129 | 75.713 ± 6.666 |
| Week 4 (n=30, 27, 19) | 78.723 ± 3.811 | 78.886 ± 3.808 | 78.823 ± 4.763 |
| Week 6/ET (n=32, 31, 40) | 66.887 ± 4.958 | 69.367 ± 5.292 | 67.015 ± 5.112 |
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=12, 17, 15) | 1.845 ± 0.247 | 1.654 ± 0.202 | 1.821 ± 0.219 |
| Week 2 (n=6, 4, 4) | 2.333 ± 0.827 | 1.667 ± 0.675 | 1.833 ± 0.893 |
| Week 4 (n=4, 3, 4) | 1.149 ± 0.615 | 2.433 ± 0.679 | 2.478 ± 0.629 |
| Week 6/ET (n=2, 5, 6) | 1.526 ± 1.346 | 4.174 ± 0.784 | 3.878 ± 0.765 |
Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge (n=12, 17, 15) | 2.260 ± 0.258 | 1.696 ± 0.211 | 2.051 ± 0.229 |
| Week 2 (n=6, 4, 4) | 2.333 ± 0.827 | 1.667 ± 0.675 | 1.833 ± 0.893 |
| Week 4 (n=4, 3, 4) | 1.418 ± 0.713 | 2.612 ± 0.788 | 2.537 ± 0.730 |
| Week 6/ET (n=2, 5, 6) | 2.067 ± 1.403 | 4.233 ± 0.817 | 3.900 ± 0.797 |
The Global Evaluation of Study Medication is a subject-administered single item instrument that records the subject's overall impression (global evaluation) of the study medication by asking the following question: how would you rate the study medication you received for pain? The subject chooses based on a scale of 1 (poor), 2 (fair), 3 (good), or 4 (excellent).
| participants | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Discharge, Excellent (n=85, 84, 78) | 31 | 27 | 19 |
| Discharge, Good (n=85, 84, 78) | 31 | 46 | 39 |
| Discharge, Fair (n=85, 84, 78) | 14 | 6 | 12 |
| Discharge, Poor (n=85, 84, 78) | 9 | 5 | 8 |
| Week 2, Excellent (n=22, 20, 18) | 6 | 10 | 5 |
| Week 2, Good (n=22, 20, 18) | 11 | 4 | 9 |
| Week 2, Fair (n=22, 20, 18) | 3 | 4 | 1 |
| Week 2, Poor (n=22, 20, 18) | 2 | 2 | 3 |
| Week 4, Excellent (n=30, 27, 19) | 13 | 9 | 7 |
| Week 4, Good (n=30, 27, 19) | 11 | 12 | 8 |
| Week 4, Fair (n=30, 27, 19) | 4 | 3 | 3 |
| Week 4, Poor (n=30, 27, 19) | 2 | 3 | 1 |
| Week 6/ET, Excellent (n=32, 31, 40) | 3 | 7 | 5 |
| Week 6/ET, Good (n=32, 31, 40) | 17 | 9 | 19 |
| Week 6/ET, Fair (n=32, 31, 40) | 6 | 5 | 7 |
| Week 6/ET, Poor (n=32, 31, 40) | 6 | 10 | 9 |
The presence of persistent pain was evaluated on the 11-point VRS. The subject answered the question: how much pain did you experience in the last 24 hours in your operated knee? A zero score of VRS was the only number considered as a "no." Any positive score (1-10) of VRS was consider as "yes."
| participants | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Month 3, Yes (n=65, 59, 61) | 22 | 22 | 27 |
| Month 3, No (n=65, 59, 61) | 43 | 37 | 34 |
| Month 6, Yes (n=64, 62, 61) | 19 | 15 | 14 |
| Month 6, No (n=64, 62, 61) | 45 | 47 | 47 |
NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.
| scores on a scale | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Burning Spontaneous Pain, Month 3, (n=23, 24, 29) | 1.348 ± 2.479 | 0.792 ± 2.085 | 0.828 ± 1.947 |
| Burning Spontaneous Pain, Month 6, (n=22, 15, 15) | 1.091 ± 2.114 | 1.400 ± 2.324 | 0.667 ± 1.113 |
| Pressing Spontaneous Pain, Month 3, (n=23, 24, 29) | 1.457 ± 2.083 | 0.958 ± 1.574 | 0.948 ± 1.496 |
| Pressing Spontaneous Pain, Month 6, (n=22, 15, 15) | 1.409 ± 2.158 | 1.333 ± 1.655 | 0.633 ± 1.445 |
| Paroxysmal Pain, Month 3, (n=23, 24, 29) | 0.804 ± 1.042 | 1.688 ± 2.417 | 1.086 ± 1.909 |
| Paroxysmal Pain, Month 6, (n=22, 15, 15) | 1.205 ± 2.711 | 1.133 ± 2.175 | 0.533 ± 1.246 |
| Evoked Pain, Month 3, (n=23, 24, 29) | 1.174 ± 1.700 | 1.319 ± 2.004 | 0.931 ± 1.344 |
| Evoked Pain, Month 6, (n=22, 15, 15) | 0.636 ± 0.937 | 1.667 ± 2.402 | 0.711 ± 1.298 |
| Paresthesia/Dysesthesia, Month 3, (n=23, 24, 29) | 0.848 ± 1.473 | 0.604 ± 1.406 | 0.690 ± 1.160 |
| Paresthesia/Dysesthesia, Month 6, (n=22, 15, 15) | 0.773 ± 1.674 | 0.500 ± 1.086 | 0.033 ± 0.129 |
| Total Score, Month 3, (n=23, 24, 29) | 0.058 ± 0.061 | 0.055 ± 0.075 | 0.045 ± 0.059 |
| Total Score, Month 6, (n=22, 15, 15) | 0.051 ± 0.074 | 0.061 ± 0.078 | 0.027 ± 0.036 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin (150 mg) | — | 11/98 (11.2%) | 76/98 (77.6%) |
| Pregabalin (300 mg) | — | 11/96 (11.5%) | 76/96 (79.2%) |
| Placebo | — | 5/98 (5.1%) | 81/98 (82.7%) |
| Event | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/98 | 3/96 | 0/98 |
| Deep vein thrombosisVascular disorders | 0/98 | 2/96 | 0/98 |
| FallInjury, poisoning and procedural complications | 2/98 | 0/96 | 0/98 |
| Cardiac failure congestiveCardiac disorders | 0/98 | 1/96 | 0/98 |
| Porcelain gallbladderHepatobiliary disorders | 0/98 | 1/96 | 0/98 |
| Anaphylactic reactionImmune system disorders | 0/98 | 1/96 | 0/98 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/98 | 1/96 | 0/98 |
| Joint range of motion decreasedMusculoskeletal and connective tissue disorders | 1/98 | 1/96 | 0/98 |
| DepressionPsychiatric disorders | 0/98 | 1/96 | 0/98 |
| HypotensionVascular disorders | 1/98 | 1/96 | 0/98 |
| Event | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 29/98 | 31/96 | 51/98 |
| ConstipationGastrointestinal disorders | 24/98 | 12/96 | 30/98 |
| DizzinessNervous system disorders | 20/98 | 25/96 | 16/98 |
| VomitingGastrointestinal disorders | 14/98 | 15/96 | 25/98 |
| SomnolenceNervous system disorders | 24/98 | 22/96 | 20/98 |
| PruritusSkin and subcutaneous tissue disorders | 15/98 | 12/96 | 21/98 |
| FatigueGeneral disorders | 20/98 | 15/96 | 19/98 |
| InsomniaPsychiatric disorders | 8/98 | 12/96 | 17/98 |
| PyrexiaGeneral disorders | 13/98 | 16/96 | 5/98 |
| HypotensionVascular disorders | 12/98 | 11/96 | 5/98 |
| Age, Customized(participants) | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo | Total |
|---|---|---|---|---|
| 18 to 44 years | 1 | 2 | 4 | 7 |
| 45 to 64 years | 52 | 44 | 49 | 145 |
| > = 65 years | 45 | 50 | 45 | 140 |
| Sex: Female, Male(Participants) | Pregabalin (150 mg) | Pregabalin (300 mg) | Placebo | Total |
|---|---|---|---|---|
| Female | 60 | 61 | 54 | 175 |
| Male | 38 | 35 | 44 | 117 |
The record gives a start of May 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →